Beacon is working with our client partner to build awareness and prescriptions for a different treatment that can help people with hemophilia A or B with inhibitors move on from bleeds. This campaign targets HCPs, patients, and caregivers to:

  • Reinforce that living with an inhibitor can be unpredictable and that more bypassing treatment options are needed
  • Introduce the first FDA-approved bypassing treatment in over 20 years—an agent that is molecularly different from other bypassing agents
  • Position SEVENFACT as the bypassing agent that delivers rapid, predictable, and reliable control of mild/moderate bleeds to help people with hemophilia A or B with inhibitors move on with more predictability in their lives